135 related articles for article (PubMed ID: 15225829)
1. 1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure.
Dusso A; Cozzolino M; Lu Y; Sato T; Slatopolsky E
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):507-11. PubMed ID: 15225829
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease.
Cozzolino M; Lu Y; Sato T; Yang J; Suarez IG; Brancaccio D; Slatopolsky E; Dusso AS
Am J Physiol Renal Physiol; 2005 Nov; 289(5):F1096-102. PubMed ID: 15998841
[TBL] [Abstract][Full Text] [Related]
4. A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia.
Arcidiacono MV; Cozzolino M; Brancaccio D; Gallieni M; Lesma E; Carelli S; Gorio A; Di Giulio AM
J Nephrol; 2007; 20(2):228-33. PubMed ID: 17514628
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid growth and suppression in renal failure.
Lewin E; Huan J; Olgaard K
Semin Dial; 2006; 19(3):238-45. PubMed ID: 16689976
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of parathyroid hyperplasia in renal failure.
Cozzolino M; Brancaccio D; Gallieni M; Galassi A; Slatopolsky E; Dusso A
J Nephrol; 2005; 18(1):5-8. PubMed ID: 15772917
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic mechanisms for parathyroid hyperplasia.
Dusso AS; Sato T; Arcidiacono MV; Alvarez-Hernandez D; Yang J; Gonzalez-Suarez I; Tominaga Y; Slatopolsky E
Kidney Int Suppl; 2006 Jul; (102):S8-11. PubMed ID: 16810310
[TBL] [Abstract][Full Text] [Related]
8. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.
Cozzolino M; Lu Y; Finch J; Slatopolsky E; Dusso AS
Kidney Int; 2001 Dec; 60(6):2109-17. PubMed ID: 11737585
[TBL] [Abstract][Full Text] [Related]
9. The induction of C/EBPβ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.
Arcidiacono MV; Yang J; Fernandez E; Dusso A
Nephrol Dial Transplant; 2015 Mar; 30(3):423-33. PubMed ID: 25294851
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor alpha and mouse models of human breast cancer.
Humphreys RC; Hennighausen L
Oncogene; 2000 Feb; 19(8):1085-91. PubMed ID: 10713694
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D analogs as therapeutic agents: a clinical study update.
Wu-Wong JR; Tian J; Goltzman D
Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
[TBL] [Abstract][Full Text] [Related]
12. p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth.
Dusso AS; Pavlopoulos T; Naumovich L; Lu Y; Finch J; Brown AJ; Morrissey J; Slatopolsky E
Kidney Int; 2001 Mar; 59(3):855-65. PubMed ID: 11231340
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors.
Tokumoto M; Taniguchi M; Matsuo D; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S27-34. PubMed ID: 16109139
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
15. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
16. [The mechanisms of parathyroid hyperplasia and its regression].
Tokumoto M; Taniguchi M
Clin Calcium; 2007 May; 17(5):665-76. PubMed ID: 17470994
[TBL] [Abstract][Full Text] [Related]
17. Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism.
Sanchez CP; He YZ
J Am Soc Nephrol; 2005 Apr; 16(4):929-38. PubMed ID: 15728789
[TBL] [Abstract][Full Text] [Related]
18. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism.
Slatopolsky E; Brown A; Dusso A
Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S54-7. PubMed ID: 11158862
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D in normal and pathological parathyroid glands: new prospects for treating hyperparathyroidism (review).
Buchwald PC; Westin G; Akerström G
Int J Mol Med; 2005 Apr; 15(4):701-6. PubMed ID: 15754035
[TBL] [Abstract][Full Text] [Related]
20. [Enhanced expression of EGFR, TGF-alpha, EGF in hyperplastic parathyroid glands in established stage of renal failure in rats].
Orita H; Hatamura I; Saji F; Shibata M; Shiizaki K; Sakaguchi T; Negi S; Akizawa T
Clin Calcium; 2005 Sep; 15 Suppl 1():60-63; discussion 63. PubMed ID: 16411340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
